<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789410</url>
  </required_header>
  <id_info>
    <org_study_id>15-009421</org_study_id>
    <nct_id>NCT02789410</nct_id>
  </id_info>
  <brief_title>Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery</brief_title>
  <official_title>Intrathecal Morphine Versus Intrathecal Hydromorphone for Analgesia Following Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrathecal (IT) opioids are commonly administered with local anesthetic during spinal
      anesthesia for post-Cesarean delivery analgesia. Traditionally, IT morphine has been used but
      the use of IT hydromorphone is growing. A previous study has shown that the effective dose
      for postoperative analgesia in 90% patients (ED90) for both IT hydromorphone and IT morphine
      (NCT02009722). These doses were found to be 75 mcg for hydromorphone and 150 mcg for
      morphine. The current proposed study would compare the duration of analgesia of IT morphine
      vs IT hydromorphone after elective cesarean delivery. Additionally, the investigators will
      compare each drug with respect the incidence of nausea and pruritus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia is the most common anesthetic technique used for Cesarean delivery in the
      United States and across the world. Intrathecal opioids are administered with a local
      anesthetic during spinal anesthesia post-Cesarean delivery analgesia. The effectiveness of
      intrathecal morphine for post-Cesarean pain control is well established, and the use of
      intrathecal hydromorphone in this patient population is growing. No prospective studies have
      been conducted to specifically compare the efficacy of intrathecal morphine versus
      hydromorphone for post-Cesarean analgesia.

      After intrathecal administration, opioid drug disposition depends on the lipid solubility of
      the individual drug. Because of its hydrophilic nature, cerebrospinal fluid (CSF)
      concentrations of morphine decline more slowly than similar doses of lipophilic drugs. This
      accounts for more rostral spread, greater dermatomal analgesia, and longer duration of action
      when compared to highly lipophilic opioids like fentanyl and sufentanil. When used for
      post-cesarean analgesia, intrathecal morphine has a duration of action between 14-36 hours
      with wide variation between individual patients. While hydromorphone is similar chemically to
      morphine, it is more lipid soluble. This decreases its spread within the intrathecal space
      and enhances its penetration into the dorsal horn of the spinal cord where interactions with
      opioid receptors occur. These differences between the two medications may influence their
      duration of action. Theoretically, this would reduce the duration of action of intrathecal
      hydromorphone when compared with intrathecal morphine. Retrospective studies have shown that
      the analgesic benefit for intrathecal hydromorphone appears to extend at least 12 hours after
      cesarean delivery and may extend up to 24 hours.

      Although effective in reducing pain, intrathecal opioids are associated with side effects
      including pruritus, nausea, and respiratory depression. A meta-analysis reviewing
      twenty-eight studies which investigated intrathecal morphine versus placebo demonstrated
      moderate increases in the incidences of pruritus, nausea and vomiting. In fact the incidence
      of nausea with IT morphine has been reported to be nearly 33%. The differences in
      pharmacokinetics between morphine and hydromorphone may also create differences in side
      effect profiles. Some studies have found that hydromorphone causes less nausea and pruritus
      than morphine, while others have not. Although opioid-induced respiratory depression is a
      rare event, studies evaluating intrathecal hydromorphone for post-Cesarean delivery pain have
      not reported any cases of respiratory depression.

      In this study, the investigators aim to compare the duration of analgesia of intrathecal
      morphine vs. hydromorphone for analgesia after cesarean delivery. Secondarily, the
      investigators will compare the side effects of each drug, including nausea and pruritus. To
      achieve the goals of this study, it is important to study equipotent doses of these
      medications. Previous work by the investigators of this study found that the effective dose
      for postoperative analgesia in 90% of patients (ED90) is 75 micrograms for intrathecal
      hydromorphone and 150 micrograms for intrathecal morphine. However, it is not known if these
      two equipotent medication doses provide a similar duration of analgesia.

      The investigators hypothesize that 150 mcg of intrathecal morphine will result in a longer
      duration of analgesia when compared to 75 micrograms of intrathecal hydromorphone.
      Additionally, the investigators hypothesize that there will be more pruritus in the
      intrathecal hydromorphone group early after surgery, and no difference in side effects at 24
      hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration</measure>
    <time_frame>24 hours after administration of spinal anesthesia</time_frame>
    <description>Each patient will be interviewed by a member of the study team 24 hours after receiving their spinal anesthetic. Patients will be asked to rate their current level of pain on a Numeric Rating Scale (NRS) of 0 (no pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>24 hours after administration of spinal anesthesia</time_frame>
    <description>The number of subjects who experienced and self-reported nausea within the first 24 hours after administration of spinal anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>24 hours after administration of spinal anesthesia</time_frame>
    <description>The number of subjects who experienced and self-reported pruritus within the first 24 hours after administration of spinal anesthesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Analgesia, Obstetrical</condition>
  <condition>Obstetric Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
    <arm_group_label>Intrathecal morphine</arm_group_label>
    <other_name>Duramorph</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
    <arm_group_label>Intrathecal hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical status II-III women presenting
             for elective cesarean delivery

          -  Term gestation (37-42 weeks)

          -  Desire to have a spinal anesthesia technique for cesarean delivery

        Exclusion Criteria:

          -  Any contraindication to the administration of a spinal technique for anesthesia

          -  History of intolerance or adverse reaction to opioid medications

          -  Chronic pain syndrome or current opioid use &gt;30 oral morphine equivalents/day

          -  Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone

          -  Current BMI &gt; 50
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans P Sviggum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology. 2005 Sep;103(3):645-53.</citation>
    <PMID>16129992</PMID>
  </reference>
  <reference>
    <citation>Sviggum HP, Arendt KW, Jacob AK, Niesen AD, Johnson RL, Schroeder DR, Tien M, Mantilla CB. Intrathecal Hydromorphone and Morphine for Postcesarean Delivery Analgesia: Determination of the ED90 Using a Sequential Allocation Biased-Coin Method. Anesth Analg. 2016 Sep;123(3):690-7. doi: 10.1213/ANE.0000000000001229.</citation>
    <PMID>26974022</PMID>
  </reference>
  <reference>
    <citation>Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. Anaesthesia. 2009 Jun;64(6):643-51. Review.</citation>
    <PMID>19462494</PMID>
  </reference>
  <reference>
    <citation>Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology. 1999 Feb;90(2):437-44. Erratum in: Anesthesiology 1999 Apr;90(4):1241.</citation>
    <PMID>9952150</PMID>
  </reference>
  <reference>
    <citation>Terajima K, Onodera H, Kobayashi M, Yamanaka H, Ohno T, Konuma S, Ogawa R. Efficacy of intrathecal morphine for analgesia following elective cesarean section: comparison with previous delivery. J Nippon Med Sch. 2003 Aug;70(4):327-33.</citation>
    <PMID>12928713</PMID>
  </reference>
  <reference>
    <citation>Beatty NC, Arendt KW, Niesen AD, Wittwer ED, Jacob AK. Analgesia after Cesarean delivery: a retrospective comparison of intrathecal hydromorphone and morphine. J Clin Anesth. 2013 Aug;25(5):379-383. doi: 10.1016/j.jclinane.2013.01.014. Epub 2013 Aug 17.</citation>
    <PMID>23965210</PMID>
  </reference>
  <reference>
    <citation>Rauch E. Intrathecal hydromorphone for postoperative analgesia after cesarean delivery: a retrospective study. AANA J. 2012 Aug;80(4 Suppl):S25-32.</citation>
    <PMID>23248827</PMID>
  </reference>
  <reference>
    <citation>Rauch E. Intrathecal hydromorphone for cesarean delivery: in search of improved postoperative pain management: a case report. AANA J. 2011 Oct;79(5):427-32.</citation>
    <PMID>23256273</PMID>
  </reference>
  <reference>
    <citation>Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth. 2003 May;90(5):665-70.</citation>
    <PMID>12697596</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2019</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hans P. Sviggum, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Cesarean delivery</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Intrathecal opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02789410/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
        <group group_id="P2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
        <group group_id="B2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="4.4"/>
                    <measurement group_id="B2" value="31.9" spread="4.3"/>
                    <measurement group_id="B3" value="31.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration</title>
        <description>Each patient will be interviewed by a member of the study team 24 hours after receiving their spinal anesthetic. Patients will be asked to rate their current level of pain on a Numeric Rating Scale (NRS) of 0 (no pain) to 10 (worst pain imaginable).</description>
        <time_frame>24 hours after administration of spinal anesthesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration</title>
          <description>Each patient will be interviewed by a member of the study team 24 hours after receiving their spinal anesthetic. Patients will be asked to rate their current level of pain on a Numeric Rating Scale (NRS) of 0 (no pain) to 10 (worst pain imaginable).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2.5" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.132</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>The number of subjects who experienced and self-reported nausea within the first 24 hours after administration of spinal anesthesia.</description>
        <time_frame>24 hours after administration of spinal anesthesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea</title>
          <description>The number of subjects who experienced and self-reported nausea within the first 24 hours after administration of spinal anesthesia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.590</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus</title>
        <description>The number of subjects who experienced and self-reported pruritus within the first 24 hours after administration of spinal anesthesia.</description>
        <time_frame>24 hours after administration of spinal anesthesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intrathecal Hydromorphone</title>
            <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
          <group group_id="O2">
            <title>Intrathecal Morphine</title>
            <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus</title>
          <description>The number of subjects who experienced and self-reported pruritus within the first 24 hours after administration of spinal anesthesia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study treatment follow up was defined as 36 hours following last administration of study treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intrathecal Hydromorphone</title>
          <description>Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
        <group group_id="E2">
          <title>Intrathecal Morphine</title>
          <description>Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hans P. Sviggum</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-9697</phone>
      <email>sviggum.hans@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

